Medical Research Network’s Post

Patient Activate simplifies patient identification for biopharma companies by offering a clear, compliant solution that's changing the landscape of finding and activating patients in rare and specialty disease. The Ambit difference is clear. Request a custom demo: https://hubs.li/Q02vSh6K0 #patientfinding #raredisease #patientactivate #dynamicleadgen #thesolutionishere #thedifferenceisclear

We often talk about early detection - catching disease early before it can cause harm. This is a critical area of changing healthcare to a proactive approach. However, at Fountain Life, we also focus on disease reversal and health optimization. Stefana's story is one example of the many lives we change every day at Fountain Life. We believe your best life is ahead of you - and through advanced diagnostic tools and therapeutics, we can help make that a reality. Watch Stefana's full story on our Youtube Channel: https://bit.ly/3Pm9W6q

It’s more important than ever to have reliable data points and personalized trial strategies. At #Emmes, we’ve developed personalized, validated assessments that extend beyond primary endpoints. By collaborating with key opinion leaders and regulators, we ensure that novel, patient-centered outcomes are recognized, leading to treatments that effectively meet patients' needs. To learn more about how Emmes defines success in pediatric rare disease trials, download our whitepaper https://hubs.la/Q02n3jh40 #PatientFocused #ClinicalTrials #RareDisease #CROpartner #clinicalTrialsInnovation #RareDiseaseDay2024 #ShareYourColours #LightUpForRare

Ferrante, et al. present the results of their study, “Maintenance risankizumab sustains induction response in patients with Crohn’s disease in a randomized Phase 3 trial.” The authors report that subcutaneous risankizumab maintenance therapy results in durable improvement in clinical and endoscopic outcomes over 1 year in patients with moderately to severely active Crohn’s disease. You can find the full paper summary on the IMID Forum completely free along with the latest updates in #Crohn’sDisease https://ow.ly/KbUt50Si7AS

Second Panel Highlights In the second panel of the conference, coordinated by Rozalina Lapadatu, President of the Autoimmune Disease Patients Association, the discussion centered on the challenges in recruiting patients for clinical trials. After a day brimming with new information, Dr. Cristina Florescu Moraid summarized the main ideas and conclusions. She also addressed questions from the audience during the Q&A session. #symposium #clinicaltrials #clinicaltrialstraining

⏳ Only a few hours remain till our final webinar! Register now if you haven't done so already: https://lnkd.in/epKv9knb⏳ The webinar will explore the skills required in implementing a step‑wise approach for patients with or at risk of developing #cardiovascular disease, recognising the risk and understanding the management of #hyperkalaemia, and discussing the latest recommendations for additional risk-based therapies in #CKD. #KidneyHealthforAll #ChronicKidneyDisease #CVD KDIGO

Natural history studies can support approvals of new rare disease therapies. If you integrate these real-world, protocol-driven studies into the early clinical development planning process, there will be a host of benefits: https://bit.ly/3VYvmJr #raredisease #realworldstudies

The phase III KEYNOTE-A18 trial reports extended survival with the addition of pembrolizumab to concurrent #chemoradiotherapy (CRT) in locally advanced #CervicalCancer, and supports this strategy as a new standard of care in patients with high-risk disease. Data from a second interim analysis presented at #ESMO24 showed that while median OS was not reached in either arm, the 36-month OS rate was significantly improved with pembrolizumab plus CRT versus CRT alone. The treatment offers a greater chance of cure compared with existing therapies, comments Remi Nout. 📌 Read the full news on the #ESMODailyReporter https://ow.ly/PIFE50TnAuR

Second Panel Highlights In the second panel of the conference, coordinated by Rozalina Lapadatu, President of the Autoimmune Disease Patients Association, the discussion centered on the challenges in recruiting patients for clinical trials. After a day brimming with new information, Dr. Cristina Florescu Moraid summarized the main ideas and conclusions. She also addressed questions from the audience during the Q&A session. #symposium #clinicaltrials #clinicaltrialstraining

Natural history studies can support approvals of new rare disease therapies. If you integrate these real-world, protocol-driven studies into the early clinical development planning process, there will be a host of benefits: https://bit.ly/4cwtkas #raredisease #clinicalstudies